ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201831
CHEMBL1201831
Compound Name CERTOLIZUMAB PEGOL
ChEMBL Synonyms CDP870 | Cimzia | PHA-738144 | CDP-870 | CERTOLIZUMAB PEGOL
Max Phase 4 (Approved)
Trade Names Cimzia

Sources

  • British National Formulary
  • Clinical Candidates
  • Manually Added Drugs
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL1201831 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
TNF-alpha inhibitor TNF-alpha DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
COLITIS, ULCERATIVED003093EFO:0000729ULCERATIVE COLITIS2ClinicalTrials
CYSTITIS, INTERSTITIALD018856EFO:1000869CHRONIC INTERSTITIAL CYSTITIS3ClinicalTrials
ARTHRITIS, RHEUMATOIDD001172EFO:0000685RHEUMATOID ARTHRITIS4ClinicalTrials
DailyMed
SPONDYLITIS, ANKYLOSINGD013167EFO:0003898ANKYLOSING SPONDYLITIS4ClinicalTrials
DailyMed
ARTHRITIS, PSORIATICD015535EFO:0003778PSORIATIC ARTHRITIS4DailyMed
PSORIASISD011565EFO:0000676PSORIASIS3ClinicalTrials
ARTHRITIS, JUVENILED001171EFO:0002609CHRONIC CHILDHOOD ARTHRITIS3ClinicalTrials
CROHN DISEASED003424EFO:0000384CROHN'S DISEASE4ClinicalTrials
DailyMed

Clinical Data

ClinicalTrials.gov CERTOLIZUMAB PEGOL
The Cochrane Collaboration CERTOLIZUMAB PEGOL

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 - IMMUNOSUPPRESSANTS
L04A - IMMUNOSUPPRESSANTS
L04AB - Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB05 - certolizumab pegol

ChemSpider ChemSpider Identifier not yet assigned
DailyMed certolizumab pegol
Wikipedia Certolizumab_pegol
spacer
spacer